Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Merck hands over $20M in IBD drug target deal with Flagship’s Quotient

Merck hands over $20M in IBD drug target deal with Flagship’s Quotient

  • March 23, 2026

Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic genomics platform.

Leave A Comment

Fields (*) Mark are Required